A1 Refereed original research article in a scientific journal

Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2FPEF score




AuthorsLaenens, Dorien; Zegkos, Thomas; Kamperidis, Vasileios; Wong, Raymond C. C.; Li, Tony Yi-Wei; Sia, Ching-Hui; Kong, William K. F.; Efthimiadis, Georgios; Poh, Kian Keong; Ziakas, Antonios; Bax, Jeroen J.; Ajmone Marsan, Nina

PublisherJohn Wiley & Sons

Publication year2024

JournalEuropean Journal of Heart Failure

Journal name in sourceEuropean journal of heart failure

Journal acronymEur J Heart Fail

Volume26

Issue10

First page 2173

Last page2182

ISSN1388-9842

eISSN1879-0844

DOIhttps://doi.org/10.1002/ejhf.3413

Web address https://doi.org/10.1002/ejhf.3413

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/457732637


Abstract

Aims

The aim of this study was to investigate whether the H2FPEF score, which was developed to improve the diagnosis of heart failure (HF) with preserved ejection fraction, is associated with HF outcomes in patients with hypertrophic cardiomyopathy (HCM).

Methods and results

Patients with HCM and preserved left ventricular ejection fraction (LVEF ≥50%) were included from a multicentre registry and the H2FPEF score was calculated. Patients were divided into three groups: low (0-1), intermediate (2-5) and high (6-9) H2FPEF score. The primary combined endpoint was a composite of all-cause death and HF admissions, while the secondary endpoints were all-cause death and HF admissions separately. A total of 955 patients were included (age 51 ± 17 years, 310 [32.5%] female). Patients with a high H2FPEF score (n = 105) were more often female, and presented with more symptoms and comorbidities. On echocardiography, patients with a high H2FPEF score had lower LVEF, more impaired diastolic function and more frequently left ventricular outflow tract obstruction. During follow-up (median 90 months [interquartile range 49-176]), 103 (11%) patients died and 57 (6%) patients had a first HF hospitalization. Event-free survival rate for the primary combined and secondary endpoints was lower for patients with an intermediate and high H2FPEF score. On multivariate Cox regression analysis, female sex (hazard ratio [HR] 1.670, 95% confidence interval [CI] 1.157-2.410; p = 0.006), Asian ethnicity (HR 6.711, 95% CI 4.076-11.048; p < 0.001), ischaemic heart disease (HR 1.732, 95% CI 1.133-2.650; p =  0.011), left atrial diameter (HR 1.028, 95% CI 1.005-1.051; p = 0.016) and intermediate (HR 2.757, 95% CI 1.612-4.713; p < 0.001) or high H2FPEF score (HR 3.689, 95% CI 1.908-7.134; p < 0.001) were independently associated with the primary combined endpoint.

Conclusion

The H2FPEF score is independently associated with HF outcome in patients with HCM and may be considered for risk stratification.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
Conflict of interest: The Department of Cardiology of Leiden University Medical Center received research grants from Abbott Vascular, Alnylam, Bayer, Biotronik, Bioventrix, Boston Scientific, Edwards Lifesciences, GE Healthcare, Medis Medical Imaging, Medtronic, Novartis, Pfizer and Pie Medical. G.E. received speaker fees from Genesis Pharma and Pfizer. A.Z. received speaker fees from AstraZeneca and Boehringer Ingelheim. J.J.B. received speaker fees from Abbott Vascular, Edwards Lifesciences and Omron. N.A.M. received speaker fees from Abbott Vascular, Philips Ultrasound, Pfizer, Omron and GE Healthcare. All other authors have nothing to disclose.


Last updated on 2025-27-02 at 13:00